1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

ViiV's licensing talks with Medicines Patent Pool progressing towards a deal

 
• By Anju Ghangurde

ViiV Healthcare, the specialist HIV joint venture formed by GlaxoSmithKline (which owns 85%) and Pfizer (15%) in late 2009, and the Medicines Patent Pool appear to have made considerable progress in their negotiations towards a potential licensing pact for ViiV's products.

ViiV Healthcare, the specialist HIV joint venture formed by GlaxoSmithKline (which owns 85%) and Pfizer (15%) in late 2009, and the Medicines Patent Pool appear to have made considerable progress in their negotiations towards a potential licensing pact for ViiV's products.

ViiV and Gilead were among the first few companies with which the Pool had initiated formal discussions, although ViiV had in the past appeared to have preferred offering its own...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

More from Therapeutic Category

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.